Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis

Gut. 2008 Jun;57(6):814-20. doi: 10.1136/gut.2007.137489. Epub 2008 Feb 4.

Abstract

Background and aims: Risk factors for mortality and re-bleeding following acute variceal haemorrhage (AVH) are incompletely understood. The aim of this study was to determine risk factors for 6-week mortality, and re-bleeding within 5 days in patients with cirrhosis and AVH.

Methods: Kaplan-Meier and Cox proportional hazards regression analyses were used to determine risk factors among 256 patients with AVH entered into a randomised, prospective trial.

Results: Thirty-five patients (14%) died within 6 weeks of AVH; 14 deaths (40%) occurred within 5 days. Only the Model for End-stage Liver Disease (MELD) score and units of packed red blood cells (PRBCs) transfused in the first 24 h were associated with 6-week mortality univariately (HR 1.11, p < 0.001; HR 1.22, p < 0.001) and bivariately (HR MELD = 1.10, p < 0.001; HR per unit of PRBCs transfused = 1.15, p = 0.005). Re-bleeding within 5 days occurred in 37 patients (15%); MELD score (p = 0.01) and a clot on a varix (p = 0.05) predicted re-bleeding. Patients with a MELD score > or = 18; both MELD score > or = 18 and > or = 4 units of PRBCs transfused; both MELD score > or = 18 and active bleeding at index endoscopy; and variceal re-bleeding had increased risk of death 6 weeks post-AVH (HR = 7.4, p < 0.001; 11.3, p < 0.001; 9.9, p < 0.001; 10.2, p < 0.001 respectively).

Conclusions: Patients with AVH and MELD score > or = 18, requiring > or = 4 units of PRBCs within the first 24 h or with active bleeding at endoscopy are at increased risk of dying within 6 weeks. MELD score > or = 18 is also a strong predictor of variceal re-bleeding within the first 5 days.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Combined Modality Therapy
  • Epidemiologic Methods
  • Esophageal and Gastric Varices / etiology*
  • Esophagoscopy
  • Female
  • Gastrointestinal Hemorrhage / drug therapy
  • Gastrointestinal Hemorrhage / etiology*
  • Humans
  • Liver Cirrhosis / complications*
  • Male
  • Middle Aged
  • Peptides, Cyclic / therapeutic use
  • Prognosis
  • Recurrence
  • Severity of Illness Index
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • Treatment Outcome

Substances

  • Peptides, Cyclic
  • lanreotide
  • Somatostatin